Table 2. Pharmacological management of multi-drug resistant (MDR) tuberculosis (TB).
| First-line oral drugs | Injectable bactericidal drugs# | Fluoroquinolones# | Second-line bacteriostatic drugs | Other drugs with unclear or unproven efficacy |
| Rifampicin ¶ | Streptomycin | Moxifloxacin | Cycloserine | Clofazimine |
| Isoniazid¶ | Amikacin | Gatifloxacin | p-aminosalicyclic acid | Clarithromycin |
| Rifabutin | Kanamycin | Ofloxacin | Prothionamide | Amoxicillin/clavulanate |
| Ethanmbutol | Capreomycin | Levofloxacin | Ethionamide | Linezolid |
| Pyrizinamide | Terizidone | Imipenem/cilastatin | ||
| Thioacetazone | ||||
| High-dose isoniazid | ||||
| Order in which drugs are added to MDR-TB regimen → | ||||
#: all MDR-TB regimens should include one injectable and one fluoroquinolone where possible; ¶: by definition, isolates classed as MDR will be resistant to these drugs.